# LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

> **NCT01271725** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 74 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Vinorelbine 25 mg/m2 weekly
- **DRUG:** Afatinib 40mg once daily (OD)
- **DRUG:** Paclitaxel 80 mg/m2 weekly

## Key facts

- **NCT ID:** NCT01271725
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-24
- **Primary completion:** 2017-03-13
- **Final completion:** 2017-03-13
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2019-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01271725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01271725, "LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01271725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*